Daniel Lynch Sells 400 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stock

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Director Daniel Lynch sold 400 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $60.00, for a total transaction of $24,000.00. Following the transaction, the director now directly owns 130,544 shares in the company, valued at $7,832,640. This trade represents a 0.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Daniel Lynch also recently made the following trade(s):

• On Monday, February 10th, Daniel Lynch sold 175,000 shares of SpringWorks Therapeutics stock. The stock was sold at an average price of $54.46, for a total value of $9,530,500.00.

SpringWorks Therapeutics Stock Performance

Shares of NASDAQ SWTX opened at $59.93 on Friday. The stock’s 50 day moving average price is $40.70 and its 200-day moving average price is $37.47. SpringWorks Therapeutics, Inc. has a twelve month low of $28.21 and a twelve month high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative return on equity of 48.21% and a negative net margin of 203.09%. As a group, research analysts anticipate that SpringWorks Therapeutics, Inc. will post -3.17 EPS for the current fiscal year.

Hedge Funds Weigh In On SpringWorks Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in SWTX. Creative Planning bought a new stake in SpringWorks Therapeutics in the third quarter worth about $254,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of SpringWorks Therapeutics by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock worth $87,000 after purchasing an additional 474 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of SpringWorks Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,285 shares of the company’s stock worth $458,000 after purchasing an additional 5,582 shares during the period. Principal Financial Group Inc. raised its holdings in shares of SpringWorks Therapeutics by 102.5% in the 3rd quarter. Principal Financial Group Inc. now owns 918,445 shares of the company’s stock worth $29,427,000 after purchasing an additional 464,903 shares during the period. Finally, Assetmark Inc. lifted its stake in SpringWorks Therapeutics by 13.7% in the third quarter. Assetmark Inc. now owns 46,020 shares of the company’s stock valued at $1,474,000 after purchasing an additional 5,546 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms have weighed in on SWTX. Evercore ISI raised their price objective on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Guggenheim dropped their price target on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Wedbush reiterated an “outperform” rating and set a $81.00 price target on shares of SpringWorks Therapeutics in a report on Thursday. Finally, HC Wainwright restated a “buy” rating and set a $74.00 price objective on shares of SpringWorks Therapeutics in a research note on Wednesday, February 12th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SpringWorks Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $71.50.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.